Semax: The Peptide Behind BDNF, Cognition, and Neuroprotection Research
- Golden State BIO
- 5 days ago
- 6 min read
Semax is a synthetic heptapeptide first developed in the Soviet Union in the 1980s as a stabilized analog of ACTH(4-10), the fragment of adrenocorticotropic hormone responsible for its neurological — but not corticotropic — activity. Decades of Russian pharmacological research have positioned it as one of the most studied nootropic and neuroprotective peptides, credited with upregulating BDNF expression, modulating dopaminergic and serotonergic tone, and supporting recovery in ischemic injury models. This piece surveys what the research says about its structure, mechanism, pharmacokinetics, and the open questions that keep it an active subject of laboratory investigation.
What Is Semax?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was synthesized by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences by extending the ACTH(4-7) core sequence. The classic corticotropin fragment is His-Phe-Arg-Trp, but Semax instead retains only His-Phe and appends a Pro-Gly-Pro tripeptide tail. That tail is the key structural innovation: it shields the peptide from rapid degradation by blood and tissue aminopeptidases, extending its functional window long enough to exert central nervous system effects. Because Semax lacks the N-terminal residues required to activate adrenal steroidogenesis, researchers describe it as functionally dissociated from ACTH's classic endocrine role while retaining and amplifying its neurological signaling.
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro, molecular weight approximately 751 Da
Classified as a melanocortin-derived neuropeptide rather than a hormone in the classic ACTH sense
Registered as a prescription nasal drug in Russia and several CIS countries — not FDA-approved in the United States
Structurally engineered specifically to resist enzymatic degradation relative to native ACTH fragments
The Mechanism: BDNF and the Melanocortin System
Semax's central nervous system activity is attributed largely to melanocortin receptor engagement — primarily MC4R in brain tissue, distinct from the adrenal MC2R pathway that drives cortisol release. Downstream of this receptor activity, rodent studies report measurable increases in BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the hippocampus and cortex, alongside shifts in dopamine and serotonin turnover in the prefrontal cortex. Semax has also demonstrated antioxidant activity in ischemia models, reducing lipid peroxidation markers associated with reperfusion injury.
Increases BDNF mRNA and protein expression in hippocampus and cortex within hours of administration in rodent models
Engages melanocortin receptors (largely MC4R) in CNS tissue, distinct from adrenal MC2R
Modulates dopamine and serotonin turnover in the prefrontal cortex
Exhibits antioxidant activity, reducing lipid peroxidation markers in ischemia models
Cognitive and Neuroprotective Research Findings
Preclinical work on Semax spans learning and memory paradigms as well as ischemic injury models. Passive-avoidance and Morris water maze studies report improved acquisition and retention, and Semax has been shown to reverse MK-801-induced amnesia in rodents, a model commonly used to study NMDA-receptor-related memory disruption. In middle cerebral artery occlusion (MCAO) stroke models, Semax administration is associated with reduced infarct volume and improved neurological scoring. Published Russian clinical literature extends this into human research contexts, examining nasal Semax formulations in post-stroke rehabilitation, pediatric attention-related cognitive research, and optic nerve atrophy.
Preclinical passive-avoidance and Morris water maze studies show improved acquisition and retention
Reverses MK-801-induced amnesia in rodent models, implicating NMDA-related memory pathways
Rodent MCAO stroke models show reduced infarct volume and improved neurological scoring
Russian clinical literature has examined nasal Semax in post-stroke rehabilitation, pediatric cognitive research, and optic nerve atrophy
Why Semax Is Studied Intranasally
Oral administration is not a viable route for Semax research: gastrointestinal peptidases cleave the peptide bonds before meaningful absorption can occur, and first-pass hepatic metabolism would degrade any surviving fraction. Even with its stabilizing Pro-Gly-Pro cap, Semax's plasma half-life is estimated at under 30 minutes. Intranasal delivery sidesteps both problems by exploiting direct olfactory and trigeminal nerve pathways, allowing a portion of the peptide to reach CNS tissue without relying on full systemic circulation. This is why nearly all published Semax research and Russian clinical formulations use nasal drops rather than injectable or oral products.
Oral administration is not viable — GI peptidases cleave the peptide before absorption
Plasma half-life is estimated at under 30 minutes even with the protective Pro-Gly-Pro cap
Intranasal delivery exploits olfactory and trigeminal nerve pathways toward the CNS
Nearly all Russian clinical formulations of Semax are nasal drops, not injectable or oral products
Semax vs. N-Acetyl Semax Amidate
A modified research variant, N-Acetyl Semax Amidate, adds an acetyl group to the N-terminus and an amide group to the C-terminus. The proposed rationale is improved resistance to enzymatic cleavage relative to unmodified Semax. However, independent, peer-reviewed pharmacokinetic comparisons between the two forms remain limited, and the bulk of the published human and animal literature — including the Russian clinical studies referenced above — was conducted using the original, unmodified sequence. Researchers comparing the two should treat claims about the acetylated/amidated variant's superiority as an open empirical question rather than an established finding.
N-Acetyl Semax Amidate adds an acetyl group at the N-terminus and an amide at the C-terminus
Proposed rationale is improved resistance to enzymatic cleavage compared to unmodified Semax
Independent, peer-reviewed pharmacokinetic head-to-head data remains limited
Most published clinical and preclinical literature refers to the original, unmodified Semax sequence
Handling Considerations for Research Use
As with most short-chain research peptides, Semax's stability profile depends heavily on formulation and storage conditions. Lyophilized (freeze-dried) Semax is generally stable for extended periods at -20°C when protected from light and moisture, but reconstituted solutions degrade far more quickly and should be used within the timeframe recommended for the specific preparation. Repeated freeze-thaw cycles accelerate peptide bond hydrolysis and should be avoided in any experimental protocol. As with any research peptide, purity verification via HPLC and a corresponding certificate of analysis is the baseline standard for confirming that a sample matches its labeled identity and concentration.
Lyophilized Semax is generally stable at -20°C for extended periods when protected from light and moisture
Reconstituted solutions are far less stable and should be used within the recommended window
A certificate of analysis with ≥98% HPLC purity is the baseline standard for verifying research-grade material
Repeated freeze-thaw cycles accelerate peptide bond hydrolysis and should be avoided
For related foundational context, see our guides on what peptides are and how they signal in the body, what ≥98% HPLC purity means for a certificate of analysis, and proper peptide storage and freeze-thaw best practices.
Frequently Asked Questions: Semax
What is Semax derived from?
Semax is a synthetic peptide engineered from the ACTH(4-10) fragment of adrenocorticotropic hormone. Researchers retained the His-Phe segment associated with central nervous system activity and added a Pro-Gly-Pro tail to slow enzymatic degradation, while removing the N-terminal residues needed for adrenal steroidogenic signaling.
How does Semax affect BDNF levels?
In rodent studies, Semax administration is associated with increased BDNF mRNA and protein expression in the hippocampus and cortex, typically measurable within hours of dosing. BDNF is a neurotrophin implicated in synaptic plasticity, neuronal survival, and long-term potentiation, which is why Semax is frequently studied alongside memory and learning models.
Is Semax the same as ACTH?
No. While Semax is derived from a fragment of ACTH, it does not activate the adrenal MC2 receptor pathway responsible for cortisol release. Research describes Semax as functionally dissociated from ACTH's classic endocrine role, retaining central nervous system activity without the corticotropic hormone effects.
What's the difference between Semax and N-Acetyl Semax Amidate?
N-Acetyl Semax Amidate is a modified version with an acetyl group added to the N-terminus and an amide group added to the C-terminus. The stated rationale is improved enzymatic resistance compared to unmodified Semax, though most of the peer-reviewed literature — including the Russian clinical studies — was conducted using the original, unmodified sequence.
Why is Semax studied via intranasal administration rather than injection or oral dosing?
Oral administration is not viable because gastrointestinal peptidases break down the peptide before it can be absorbed. Semax's plasma half-life is estimated at under 30 minutes even with its stabilizing Pro-Gly-Pro cap. Intranasal delivery allows a portion of the peptide to travel along olfactory and trigeminal nerve pathways directly toward the central nervous system, which is why nearly all published Semax research and Russian clinical formulations use nasal administration.
Has Semax been studied in human clinical settings?
Yes, primarily in Russia, where Semax nasal solutions are a registered prescription drug. Published Russian-language clinical literature has examined its use in post-ischemic-stroke rehabilitation, pediatric attention-related cognitive research, and optic nerve atrophy. Independent replication in peer-reviewed Western journals is more limited, which remains an active area of research interest.
Is Semax approved by the FDA?
No. Semax is not approved by the FDA for any use in the United States and is not a dietary supplement or an approved drug. It is sold and studied strictly as a research chemical for laboratory use by qualified researchers, not for human consumption.
Source Semax for Your Research
Golden State BIO supplies ≥98% HPLC-verified Semax with a certificate of analysis for every batch, formulated strictly for laboratory research use.
The Bottom Line
Semax stands out among research peptides for the depth of its mechanistic literature: a stabilized ACTH(4-10) fragment engineered specifically to survive long enough to act on melanocortin receptors, elevate BDNF expression, and modulate dopaminergic and serotonergic signaling in the central nervous system. Decades of Russian preclinical and clinical research have mapped its neuroprotective and cognitive effects in detail, even as independent Western replication and head-to-head comparisons with variants like N-Acetyl Semax Amidate remain open areas of investigation. For researchers, that combination of a well-characterized mechanism and unresolved pharmacokinetic questions is exactly what keeps Semax an active subject of laboratory study.
Comments